Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial

Publication | Closed Access

DOI

Citations

References

2021

Year

François Guilhot, Françoise Rigal‐Huguet, Joëlle Guilhot, Agnès-Paule Guerci-Bresler, Frédéric Maloisel, Delphine Réa, Valérie Coiteux, Martine Gardembas, Christian Berthou, Anne Vekhoff,

Leukemia

Hematological MalignancyInterferon Alpha 2AOncologyChronic Myeloid LeukaemiaHematologyClinical TrialsMyeloid NeoplasiaPharmacotherapyImatinib 400MedicineRadiation OncologyCancer ResearchHealth Sciences